Want to see CNSY full AI Analyst Report?
Top Page
Cerenome
(NASDAQ:CNSY)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-35.06% Downside)
Action:Reiterated
Date:10/02/26
The score is held down primarily by weak financial performance (material ongoing losses and heavy cash burn) and bearish technicals (price below all key moving averages with negative MACD and very weak RSI/Stoch). Corporate events provide some support via added financing and runway extension, but the structure introduces potential dilution/overhang, and valuation is not helped by negative earnings and no dividend metric provided.
Positive Factors
High Gross Margin
The approximately 92.8% TTM gross margin indicates that the underlying offering retains substantial value after direct costs. If revenue expands through commercialization, this margin profile could support operating leverage, although the company must still reduce substantial operating and research expenses.
Negative Factors
Declining Revenue
A small and declining revenue base limits the company’s ability to fund operations internally and indicates that commercialization has not yet produced durable scale. Continued volatility also makes forecasting more difficult and increases dependence on successful future adoption of its offerings.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
The approximately 92.8% TTM gross margin indicates that the underlying offering retains substantial value after direct costs. If revenue expands through commercialization, this margin profile could support operating leverage, although the company must still reduce substantial operating and research expenses.
Read all positive factors
Cerenome (CNSY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.21M
Dividend YieldN/A
Average Volume (3M)146.72K
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue Growth-20.95%
EPS Growth91.97%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-1033.42
Shares Outstanding7,589,774
10 Day Avg. Volume75,170
30 Day Avg. Volume146,720
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.15
Price to Sales (P/S)2.42
P/FCF Ratio-0.60
Enterprise Value/Market Cap1.64
Enterprise Value/Revenue5.14
Enterprise Value/Gross Profit5.74
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$37.00Price Target Upside1101.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.7
Revenue Forecast (FY)$6.22M
Cerenome Business Overview & Revenue Model
Company Description
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLipo...
Cerenome Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
46
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.20M | 5.21M | 5.82M | 4.91M | 224.00K | 0.00 |
| Gross Profit | 3.77M | 4.77M | 4.97M | -4.78M | -488.00K | -66.00K |
| EBITDA | -22.36M | -18.33M | -8.38M | -12.29M | -18.95M | -12.07M |
| Net Income | -26.09M | -22.39M | -12.98M | -13.32M | -20.27M | -13.40M |
Balance Sheet | ||||||
| Total Assets | 14.03M | 16.32M | 6.63M | 11.39M | 23.87M | 21.98M |
| Cash, Cash Equivalents and Short-Term Investments | 8.59M | 8.76M | 3.61M | 8.55M | 18.12M | 18.40M |
| Total Debt | 44.00K | 821.00K | 3.37M | 4.18M | 5.75M | 6.99M |
| Total Liabilities | 8.57M | 12.33M | 15.58M | 12.74M | 17.42M | 11.14M |
| Stockholders Equity | 5.46M | 4.00M | -8.95M | -1.35M | 6.45M | 10.84M |
Cash Flow | ||||||
| Free Cash Flow | -23.55M | -20.84M | -10.70M | -13.01M | -13.73M | -10.42M |
| Operating Cash Flow | -22.18M | -20.77M | -10.55M | -12.85M | -12.97M | -10.28M |
| Investing Cash Flow | -2.95M | -854.00K | -4.11M | -160.00K | -759.00K | -82.00K |
| Financing Cash Flow | 25.25M | 30.31M | 6.19M | 3.44M | 13.45M | 20.42M |
Cerenome Technical Analysis
Neutral
3.08
Price Trends
2.17
Negative
3.13
Negative
4.71
Negative
Market Momentum
-0.14
Negative
44.81
Neutral
32.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNSY, the sentiment is Neutral. The current price of 3.08 is above the 20-day moving average (MA) of 1.71, above the 50-day MA of 2.17, and below the 200-day MA of 4.71, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 44.81 is Neutral, neither overbought nor oversold. The STOCH value of 32.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CNSY.
Cerenome Risk Analysis
Cerenome disclosed 62 risk factors in its most recent earnings report. Cerenome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cerenome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $76.71M | -0.95 | -70.14% | ― | ― | 16.04% | |
45 Neutral | $11.83M | -0.32 | -145.40% | ― | -100.00% | 82.57% | |
44 Neutral | $18.87M | -0.04 | 77.63% | ― | 6.81% | 11.95% | |
42 Neutral | $13.21M | >-0.01 | -394.17% | ― | -20.95% | 91.97% | |
41 Neutral | $6.70M | -0.12 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
CNSY
Cerenome
1.74
-11.80
-87.15%
KPTI
Karyopharm Therapeutics
0.83
-5.25
-86.32%
TVRD
Tvardi Therapeutics
0.89
-3.89
-81.44%
SNTI
Senti Biosciences
0.22
-1.93
-90.00%
ACRV
Acrivon Therapeutics, Inc.
1.79
-0.10
-5.29%
Cerenome Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cerenome Updates Investor Presentation on CNS Oncology Strategy
Positive
Oct 2, 2026
On September 30, 2026, Cerenome updated its corporate presentation for investors and analysts, outlining its positioning in CNS oncology and the scale of the unmet need in metastatic CNS cancer, including an estimated 2 million Americans at risk. ...
Business Operations and StrategyPrivate Placements and Financing
Cerenome Secures New Senior Financing to Extend Runway
Positive
Sep 10, 2026
On September 4, 2026, Cerenome entered into a senior secured convertible note financing with an institutional investor for up to $21.28 million in principal across multiple tranches, with an initial closing around September 10, 2026 providing $3 m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.